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Abstract
Background: Myeloproliferative disorders are characterized by clonal expansion of normal mature blood cells. Acquired
mutations giving rise to constitutive activation of the JAK2 tyrosine kinase has been shown to be present in the majority of
patients. Since the demonstration that the V617F mutation in the exon 14 of the JAK2 gene is present in about 90% of
patients with Polycythemia Vera (PV), the detection of this mutation has become a key tool for the diagnosis of these
patients. More recently, additional mutations in the exon 12 of the JAK2 gene have been described in 5 to 10% of the
patients with erythrocytosis. According to the updated WHO criteria the presence of these mutations should be looked for
in PV patients with no JAK2 V617F mutation. Reliable and accurate methods dedicated to the detection of these highly
variable mutations are therefore necessary.
Methods/Findings: For these reasons we have defined the conditions of a High Resolution DNA Melting curve analysis
(HRM) method able to detect JAK2 exon 12 mutations. After having validated that the method was able to detect mutated
patients, we have verified that it gave reproducible results in repeated experiments, on DNA extracted from either total
blood or purified granulocytes. This HRM assay was further validated using 8 samples bearing different mutant sequences in
4 different laboratories, on 3 different instruments.
Conclusion: The assay we have developed is thus a valid method, adapted to routine detection of JAK2 exon 12 mutations
with highly reproducible results.
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Introduction
Myeloproliferative disorders (MPDs) are hematological malig-
nancies characterized by an accumulation of mature cells in the
peripheral blood. Usually, Chronic Myeloid Leukemia (CML), a
well characterized entity harbouring the recurrent t(9;22) translo-
cation and the resulting BCR-ABL1 fusion gene, is separated from
the classical MPDs such as Polycythemia Vera (PV), Essential
Thrombocytemia (ET) and Primary Myelofibrosis (PMF), in which
a molecular abnormality has long time been ignored. In the latter
group, the recurrent V617F mutation in the exon 14 of the JAK2
gene has been identified in 2005 [1–4] and is currently a key
marker for MPD diagnosis [5] as this mutation is present in 90%,
60% and 50% of PV, TE and PMF respectively [6]. In 2007, novel
recurrent mutations clustered in a highly conserved region in exon
12 of the JAK2 gene have been described in patients with PV or
Idiopathic erythrocytosis [7]. Exon 14 and exon 12 mutations
differ by 2 main characteristics: the V617F mutation is limited to
only one base change (G1846T) found in all subtypes of MPDs [6]
as well as in splanchnic vein thrombosis [8] and some
myelodysplastic syndromes patients [9]. Exon 12 mutations on
the other hands are extremely variable in sequence [10] and so far
restricted to polycythaemia patients. In a recent study, using allele
specific PCR, we reported the presence of JAK2 exon 12
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8893mutations in 8 out of 24 PV patients negative for JAK2 V617F
mutation, but failed to detect these mutations in patients with
idiopathic erythrocytosis [11].
The detection of JAK2 exon 12 mutations is technically much
more complicated than V617F mutation detection. Although some
mutants are more frequent than others there has been an increasing
number of different deletions, insertions or base changes described
in the literature since the initial description [7]. Until recently,
mutantdetection had to be addressed eitherbydirectsequencing (of
low sensitivity) or allele specific PCR (of good sensitivity) but
inadequate in a routine diagnosis setting with so many different
mutations requiring multiple individual PCR reactions.
High Resolution DNA Melting curve analysis (HRM) is based
on DNA melting in the presence of saturating DNA binding dyes.
Sequence variants are inferred from changes in the melting
transition of the PCR product as, depending on their GC content,
length or sequence, different PCR products have different melting
temperatures [12], whether mutated sequences are known or not.
HRM methods have now been adapted to real-time PCR
instruments and, compared to sequencing or AS-PCR, represent
high throughput and time saving methods with the further
advantage of reducing post-PCR handling of PCR products.
HRM technology has been adapted to the identification of
bacterial species [13] or subtypes [14], human SNP genotyping
[15] or mutation detection [16,17]. However, instruments vary
widely in their ability to genotype variants by whole amplicon
melting analysis [18,19]. Similarly, several DNA binding dyes may
be used with variable success [18,19].
Because HRM technology could be a rapid and convenient tool
for detecting the various JAK2 exon12 mutations, we decided to
develop one such method with the prerequisite that it should be
reliable enough to give similar results on 2 different instruments in
2 different sites. Then, the assay has been further validated on a
cohort of 8 different mutants and 4 non mutated DNA in 2
additional centres, of whom one functioned in a blind manner.
Materials and Methods
Patients and Samples
In accordance with our recent results [11] and previous
published studies [7] we tested patients presenting with erythro-
cytosis, low serum Epo levels and no V617F JAK2 mutation. The
method was tested on samples from 39 patients from our previous
study and 50 new patients addressed for diagnosis. DNA was
extracted from total blood or granulocytes. The local institutional
ethics committee ‘‘Comite Consultatif de Protection des Personnes
dans la Recherche Biomedicale’’ approved the study, and all
patients gave written informed consent.
HRM Method
Three instruments were used in 4 different French centres: a
LighCycler 480 (Roche Applied Sciences) in Toulouse and Brest,
an ABI 7500 fast (AppliedBiosystems) in Paris and an ABI 7900
(AppliedBiosystems) in Creteil. PCR reactions were performed in a
12 ml final volume containing 20 ng of genomic DNA and 0.2 mM
of forward (59-ACCAACCTCACCAACATTACAGAG-39) and
reverse (59-AAAAGGACAAAAAAGACAGTAATGAGTATC-
39) primers defining a 184 bp amplicon. When LightCycler
apparatus was used, the LC480 HRM master mix (Roche),
containing Resolight as DNA binding dye, was used and 3 mM
MgCl2 was added, whereas the AmpliTaq Gold PCR Master Mix
(AppliedBiosystems) with 1.5 mM of Syto-9 (Invitrogen) were used
with the ABI 7500 fast or ABI 7900 instruments. Amplification
was performed by 50 cycles of 95uC for 15 secs, 63uC for 15 secs
and 72uC for 25 secs followed by a melt according to each
manufacturer instructions.
Sequencing Analysis
PCR reactions were performed in a 20 mL reaction volume
containing the following: 10 pmol of each primer forward primer
was 59-CTCCTCTTTGGAGCAATTCA-39 and reverse primer
was 59-GAGAACTTGGGAGTTGCGATA-39, 1x PCR buffer
(Qiagen), 200 mM each dNTPS (Invitrogen), 1U of HotStarTaq
DNA polymerase (Qiagen) and 20 ng of DNA. Cycling conditions
were as follows: 95uC for 15 min, 35 cycles of 94uC for 20 s, 59uC
for 20 sec, 72uC for 45 s followed by a final elongation step at
72uC for 10 min. PCR Amplified fragment was 495 bp in length.
Sequencing analyses were performed using a fluorescent-tagged
dideoxy chain termination method with a 3130XL-DNA sequenc-
ing system (Applied Biosystem).
Results
HRM Analysis Is a Suitable Method for JAK2 Exon 12
Mutations Detection
We previously reported several JAK2 V617F negative polycy-
themia patients with JAK2 exon 12 mutations detected by allele
Figure 1. HRM analysis. HRM profiles of 7 patients known to harbor JAK2 exon 12 mutations compared to 7 controls. Analysis of total blood DNA
on the ABI7500 fast instrument.
doi:10.1371/journal.pone.0008893.g001
HRM for JAK2 Exon 12 Mutations
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8893Figure 2. Comparison between total blood and granulocyte DNA. HRM analysis performed in 2 patients on DNA extracted from total blood
or purified granulocytes from the same sample. Granulocytes in red, Blood in blue, normal controls in green. Patient 1 in upper panel; Patient 2 in
lower panel.
doi:10.1371/journal.pone.0008893.g002
Table 1. Clinical and biological data of 8 patients with exon 12 mutations tested in 4 laboratories (RCM: Red cell mass. ND: Not
done).
Nu Age (Y) Sex
RCM (%
excess) Hematocrit (%)
WBC
(x10
9/L)
Platelets
(x10
9/L) Epo EECs Spleen Mutation
1 61 F 137 63 17 162 low ND N N542-E543del
2 66 F 68 62 5,8 274 low Yes N H538Q-K539L
3 52 M ND 67 12,5 260 low Yes N H538-K539delinsL
4 38 M ND 64 11,6 354 low ND N K539L
5 71 F 68 72 7,9 151 low ND Y I546_F547ins11
6 57 M 141 62 12,8 259 low ND N R541_E543delinsK
7 71 M 113 53 16,3 1425 ND ND N E543_D544del
8 80 F 57 57 5,6 378 low Yes N I540_N542delinsK
doi:10.1371/journal.pone.0008893.t001
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PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8893Figure 3. HRM profiles on 3 different instruments for 2 patients. Total blood DNA from 2 patients was analysed on 3 different instruments
together with non mutated DNA. Arrows show mutant DNA.
doi:10.1371/journal.pone.0008893.g003
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study we first used total blood DNA from these positive patients in
order to set up a new assay using HRM technology in 2 centres.
The assay was first developed on a Lightcycler 480 (Roche) in
Toulouse, and then tested on an ABI 7500 fast (AppliedBiosys-
tems) instrument in Paris. Using HRM method allowed to identify
every patient known to be mutated, whereas all control patients
showed a wild type profile (Figure 1). These results confirmed that
High Resolution DNA Melting curve analysis is a suitable method
for the detection of JAK2 exon 12 abnormalities.
In order to test for the reproducibility of the method we have
analysed 2 positive samples characterized by different mutant
sequences in 3 independent experiments, each performed at 1
week interval. Results were highly similar in all three experiments
(not shown), proving that the HRM method tested herein could
have sufficient robustness for a diagnostic purpose.
Though it is now widely admitted that JAK2 V617F mutations
can be detected with similar efficacy in DNA from peripheral
blood or purified granulocytes, this has not been extensively
studied for the JAK2 exon 12 mutations. We compared in 2
patients the results obtained with DNA extracted from total blood
or from purified granulocytes. Similar results were observed
whatever the source of DNA (Figure 2).
Applications of the HRM Analysis
Samples (n=39) of patients with either idiopathic erythrocytosis
or PV from our previous report [11] which were negative by AS-
PCR for exon 12 mutations were analysed by the HRM method
and were again found negative. In the analysis of new patients
addressed to our laboratories for MPD diagnosis, 9 out of 35
patients presenting with an increased hematocrit, low Epo levels
and absence of the JAK2 V617F mutation, harboured a mutation
confirmed by sequencing analysis.
Validation of the Method in 2 Additional Centres
It has been reported that important discrepancies could be
observed when one HRM method was used on different
instruments [18,19]. In a preliminary approach, we thus compared
the diagnostic accuracy of our method by analysing the 9 positive
samples on 2 instruments, in 2 separate laboratories in Toulouse
and Paris. Each laboratory used different DNA binding dyes
(Resolight on the LC480 instrument and Syto-9 on the ABI
7500 instrument) also reported to be source for discrepancies
[18,19]. Although shifting temperatures and curves shapes were
somewhat different between the two instruments, results were
undoubtedly similar in their interpretation.
The validation of the method was completed by analysing 8
samples bearing different mutated sequences (clinical data and
mutant subtypes are given in Table 1) in 2 additional laboratories,
Brest and Creteil, which had not participated in the set up of the
HRM assay. In one of the two labs (Creteil), the analysis was
performed in a completely blind manner, on12 anonymous DNA
samples (8 mutated and 4 wild type) on an ABI 7900 instrument
(AppliedBiosystems) wheras a LC480 instrument (Roche) was used
in Brest. The HRM method was equally able to discriminate
mutant from wild type samples on the 3 different instruments
tested (Figure 3 represents an example of the comparative results
obtained on different instruments). Both laboratories perfectly
identified every mutated sample, without any change in the
experimental protocol confirming this HRM method as a robust
and efficient method even in an inter-laboratory fashion.
Discussion
As WHO criteria for Polycythaemia Vera diagnosis include the
‘‘presence of JAK2 V617F or similar mutation’’ [5], detection of
JAK2 exon 12 mutations is of importance for the 5 to 10% of
patients presenting with a suspicion of PV but with no JAK2
V617F mutation. Furthermore, pharmacological JAK2 inhibitors
are, at least for some of them, equally active on V617F and JAK2
exon 12 mutations [20], reinforcing the need for a convenient tool
to detect those mutations.
Several different mutations are now described [10] in the JAK2
exon 12 clustered in a short region of about 35 bases [7], easily
studied in only one round of PCR. HRM analysis, based on the
detection of a difference in fusion temperature or a difference in
the shape of the fusion curve, is able to detect variations in the GC
content, the sequence or the length of PCR products. It has
recently been successfully adapted to detect JAK2 exon 12
mutations [21,22]. However, one difficulty in the field of HRM is
the possibility to transfer one method from one instrument to
another, because variations have been reported in comparative
studies [18,19]. For these reasons, once having defined an HRM
method which may be able to detect patients known to present
JAK2 exon 12 mutations, we validated the method as reproducible
and transferable on three different instruments using different
DNA binding dyes. The method allowed to identify mutant
patients which, as previously reported for exon 12 mutated
patients, presented with erythrocytosis and a low circulating
erythropoietin level, high WBC in the majority of them but
normal platelet counts. Similarly to the JAK2 V617F mutation
[23], exon 12 mutations can be found in all lineages, although T
lymphocytes are frequently found negatives [24]. It is thus not
surprising that similar results can be obtained from DNA extracted
from total blood or purified granulocytes. These results suggest
that, at least using HRM methods, the detection of JAK2 exon 12
mutations for MPD diagnosis may be performed with similar
efficiency on DNA from total blood or purified granulocytes.
Notably, we have reanalysed several DNA samples from patients
previously found not mutated using the AS-PCR approach, but
failed to find any additional mutated patient. Nevertheless, the
HRM method presented in this study is able to detect more
mutations than AS-PCR, is a high throughput method and much
more suitable for routine laboratory diagnosis, and is inter-
laboratory and inter-instrument reproducible.
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